How many studies have been conducted on Lymphocyte Activation Gene 3 Protein?

BiohacksAI has indexed 31 PubMed studies on Lymphocyte Activation Gene 3 Protein, including 1 randomized controlled trials (RCTs). 68% of studies involve human subjects.

What are the main research areas for Lymphocyte Activation Gene 3 Protein?

The primary research domains for Lymphocyte Activation Gene 3 Protein are 🔬 Oncology, 🛡️ Immunity, 🔬 Inflammation. This is based on analysis of 31 PubMed studies using the BiohacksAI evidence platform.

BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

Lymphocyte Activation Gene 3 Protein

A CD4-related protein with high affinity cell surface binding to MHC class II. It functions in downregulation of T cell proliferation following binding to MHC class II molecules.

31+ PubMed studies analyzed · 1 RCTs · Evidence Score: 45.2

Research Domains

Lymphocyte Activation Gene 3 Protein has been studied across 11 research domains including 🔬 Oncology, 🛡️ Immunity, 🔬 Inflammation, 🫁 Liver & Detox, 🫁 Respiratory. The primary research focus is 🔬 Oncology with 42% of studies addressing this area.

Loading evidence profile...

This evidence profile for Lymphocyte Activation Gene 3 Protein is generated deterministically from 31 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.